ERBB2 and breast cancer: In addition, MARCKS overexpression has been observed in aggressive subtypes of breast cancer, i.e., basal-like and HER2 subtypes [46], and is also associated with tumor grade, presence of metastases, and poor survival in male breast cancer and inflammatory breast cancer [47,48,49], possibly through increased MARCKS binding to Tob which decreases binding of Tob with ErbB2 and subsequent activation of ErbB2 signaling [50,51].